94 related articles for article (PubMed ID: 11760562)
1. NCCN: New applications for erythropoietin.
Demetri GD
Cancer Control; 2001; 8(6 Suppl 2):72-6. PubMed ID: 11760562
[No Abstract] [Full Text] [Related]
2. Erythropoietin therapy: need for rationality and active surveillance.
Cazzola M
Haematologica; 2003 Jun; 88(6):601-5. PubMed ID: 12801832
[No Abstract] [Full Text] [Related]
3. [Clinical use of erythropoietin].
Franchini M; Gandini G; Lippi G; De Gironcoli M; Cantini M; Aprili G
Recenti Prog Med; 2004 Mar; 95(3):129-36; quiz 185. PubMed ID: 15143948
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin use in cancer patients: a matter of life and death?
Steensma DP; Loprinzi CL
J Clin Oncol; 2005 Sep; 23(25):5865-8. PubMed ID: 16087951
[No Abstract] [Full Text] [Related]
5. Treating anemia in patients with cancer.
Tecnologica; 2001 Oct; ():1, 3-8. PubMed ID: 11776275
[No Abstract] [Full Text] [Related]
6. Quality of life in clinical trials: assessment and utility with special reference to rHuEPO.
Brandberg Y
Med Oncol; 1998 Aug; 15 Suppl 1():S8-12. PubMed ID: 9785331
[No Abstract] [Full Text] [Related]
7. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
Beutel G; Ganser A
Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
[TBL] [Abstract][Full Text] [Related]
8. EPO therapy during acute kidney disease: to use or not to use, that is the question.
Kraus E; Rabb H
Am J Kidney Dis; 2005 Nov; 46(5):967-9. PubMed ID: 16253740
[No Abstract] [Full Text] [Related]
9. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
Spaëth D
Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
[TBL] [Abstract][Full Text] [Related]
10. [Chronic lymphatic leukemia: significance of erythropoietin].
Barthel HR
Dtsch Med Wochenschr; 2002 May; 127(18):982; author reply 982-3. PubMed ID: 11987022
[No Abstract] [Full Text] [Related]
11. Use of recombinant human erythropoietin in anemia of malignancy.
Cazzola M
Med Oncol; 1998 Aug; 15 Suppl 1():S1-2. PubMed ID: 9785329
[No Abstract] [Full Text] [Related]
12. The role of recombinant erythropoietin in childhood cancer.
Shankar AG
Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
14. Target hemoglobin level for EPO therapy in CKD.
Parfrey PS
Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
[No Abstract] [Full Text] [Related]
15. [Severe, life-threatening renal anemia treatment in patients who do not accept heterologous blood transfusion for religious reasons--case report].
Jaroszyński AJ; Bober-Palak E; Jóźwiak L; Ksiazek A
Przegl Lek; 2007; 64(7-8):528-30. PubMed ID: 18409359
[TBL] [Abstract][Full Text] [Related]
16. [New preparations of erythropoietin].
Sakaguchi T; Akizawa T
Nihon Rinsho; 2004 May; 62 Suppl 5():360-3. PubMed ID: 15197945
[No Abstract] [Full Text] [Related]
17. Erythropoietin in the critically ill: what is the evidence?
Corwin HL; Eckardt KU
Nephrol Dial Transplant; 2005 Dec; 20(12):2605-8. PubMed ID: 16221691
[No Abstract] [Full Text] [Related]
18. Erythropoietin usage in patients with cancer.
Wood PA; Hrushesky WJ
Cancer J Sci Am; 1995; 1(4):243-6. PubMed ID: 9166482
[No Abstract] [Full Text] [Related]
19. [Use of human recombinant erythropoietin in children with cancer].
Guyot D; Margueritte G
Arch Pediatr; 2005 Sep; 12(9):1376-82. PubMed ID: 16084072
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
